Sun Pharma reports durable response for UNLOXCYT in skin cancer trial
Long-term data from a trial shows a 50% objective response rate for UNLOXCYT in locally advanced cutaneous squamous cell carcinoma.
— 3 earlier stories on Sun Pharmaceutical Industries Ltd. →What's new
- Sun Pharma will present long-term trial data for UNLOXCYT on May 31.
- The study shows a 50% objective response rate with 27% complete responses.
- Median duration of response remains unreached after over two years of follow-up.
Why this matters
The data confirms the durability of UNLOXCYT in a niche oncology segment. The financial impact for a company of Sun Pharma's size is incremental, but the results provide clinical credibility to its oncology franchise.
What we're watching
- Regulatory feedback following the ASCO presentation.
- Market adoption rates in the laCSCC segment.
- Potential expansion of the drug's indication.
The full read
Sun Pharma will present long-term data for UNLOXCYT at the American Society of Clinical Oncology meeting on May 31. The trial is the second largest prospective study for locally advanced cutaneous squamous cell carcinoma, reporting an objective response rate of 50%.
Twenty-seven percent of patients achieved complete responses.
Median duration of response remains unreached after over two years of follow-up, and the safety profile is manageable, with only one patient reporting a grade 3 or higher immune-related adverse event. These results add clinical weight to the drug in a specialized oncology segment. They remain incremental for a company with annual revenue exceeding ₹55,000 crore. The data provides clinical validation for the franchise. Market expectations for positive outcomes were already present.
Questions answered
- What is the primary finding of the UNLOXCYT study?
- The trial demonstrated a 50% objective response rate in patients with locally advanced cutaneous squamous cell carcinoma. 27% of patients achieved complete responses.
- How durable are the responses observed in the trial?
- The median duration of response has not yet been reached after over two years of follow-up. This indicates a high level of durability for the treatment.
- Is the drug safe for patients?
- The study reported a manageable safety profile. Only one patient experienced a grade 3 or higher immune-related adverse event.
- How significant is this data for Sun Pharma's financials?
- The impact is incremental. Sun Pharma generates over ₹55,000 crore in annual revenue, making this a niche addition to its broader portfolio.
Story so far
All notes on SUNPHARMA →- 26 May 2026 · 6:25 PM IST Sun Pharma reports durable response for UNLOXCYT in skin cancer trial
- 4d ago Sun Pharma's US innovation revenue overtakes its generics business
- 4d ago Sun Pharma posts 26% Q4 profit growth and readies tax shift
- 4d ago Sun Pharmaceutical FY26 growth hits 11.9% as dividends hold steady